Debate continues as to whether all patients with early human epidermal growth factor receptor type 2 (HER2)+ breast cancer need an anthracycline with trastuzumab. Updated data from the Breast Cancer International Research Group (BCIRG)-006 trial suggest that eliminating the anthracycline will have comparable efficacy and be less toxic.
To sign up for our newsletter or print publications, please enter your contact information below.
